Incorporation of CEA Improves Risk Stratification in Stage II Colon Cancer

Overview

Journal J Gastrointest Surg

Specialty Gastroenterology

Date 2017 Mar 15

PMID 28290141

Citations 16

Authors

Blake A Spindler

John R Bergquist

Cornelius A Thiels

Elizabeth B Habermann

Scott R Kelley

David W Larson

Kellie L Mathis

Affiliations

Soon will be listed here.

Abstract

High-risk features are used to direct adjuvant therapy for stage II colon cancer. Currently, high-risk features are identified postoperatively, limiting preoperative risk stratification. We hypothesized carcinoembryonic antigen (CEA) can improve preoperative risk stratification for stage II colon cancer. The National Cancer Database (NCDB 2004-2009) was reviewed for stage II colon adenocarcinoma patients undergoing curative intent resection. A novel risk stratification including both traditional high-risk features (T4 lesion, <12 lymph nodes sampled, and poor differentiation) and elevated CEA was developed. Unadjusted Kaplan-Meier and adjusted Cox proportional hazards analyzed overall survival. Concordance Probability Estimates (CPE) assessed discrimination. Seventy-four thousand nine hundred forty-five patients were identified; 40,844 (54.5%) had CEA levels reported and were included. Chemotherapy administration was similar between normal and elevated CEA groups (23.8 vs. 25.1%, p = 0.003). Compared to patients with CEA elevation, 5-year overall survival in patients with normal CEA was improved (74.5 vs. 63.4%, p < 0.001). Restratification incorporating CEA resulted in reclassification of 6912 patients (16.9%) from average to high risk. CPE increased for novel risk stratification (0.634 vs. 0.612, SE = 0.005). The routinely available CEA test improved risk stratification for stage II colon cancer. CEA not only may improve staging of colon cancer but may also help guide additional therapy.

Citing Articles

Conditional survival and the prognostic value of serum carcinoembryonic antigen level in oldest old with colorectal cancer.

He W, Yang Y, Liu Q, Luo D, Li Q, Li X BMC Gastroenterol. 2024; 24(1):220.

PMID: 38987680 PMC: 11234783. DOI: 10.1186/s12876-024-03318-4.

Prognostic prediction model of colorectal cancer based on preoperative serum tumor markers.

Diao Y, Rao S, Shu X, Cheng Y, Tan C, Wang L World J Gastrointest Surg. 2024; 16(5):1344-1353.

PMID: 38817280 PMC: 11135305. DOI: 10.4240/wjgs.v16.i5.1344.

Survival nomograms for simultaneous resection of primary and hepatic lesions without neoadjuvant chemotherapy in patients with resectable colorectal liver metastasis.

Jiang Y, Zhou S, Zhu Z, Chen J, Liang J Cancer Innov. 2023; 2(4):240-252.

PMID: 38089745 PMC: 10686155. DOI: 10.1002/cai2.45.

High preoperative CEA and systemic inflammation response index (C-SIRI) predict unfavorable survival of resectable colorectal cancer.

Cai H, Chen Y, Zhang Q, Liu Y, Jia H World J Surg Oncol. 2023; 21(1):178.

PMID: 37291634 PMC: 10251701. DOI: 10.1186/s12957-023-03056-z.

Biomarkers in the development of individualized treatment regimens for colorectal cancer.

Crutcher M, Waldman S Front Med (Lausanne). 2022; 9:1062423.

PMID: 36530921 PMC: 9749006. DOI: 10.3389/fmed.2022.1062423.

References

MOERTEL C, OFallon J, Go V, Oconnell M, Thynne G . The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer. 1986; 58(3):603-10. DOI: 10.1002/1097-0142(19860801)58:3<603::aid-cncr2820580302>3.0.co;2-k. View

Quah H, Chou J, Gonen M, Shia J, Schrag D, Landmann R . Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum. 2008; 51(5):503-7. DOI: 10.1007/s10350-008-9246-z. View

Raval M, Bilimoria K, Stewart A, Bentrem D, Ko C . Using the NCDB for cancer care improvement: an introduction to available quality assessment tools. J Surg Oncol. 2009; 99(8):488-90. DOI: 10.1002/jso.21173. View

Dalerba P, Sahoo D, Paik S, Guo X, Yothers G, Song N . CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med. 2016; 374(3):211-22. PMC: 4784450. DOI: 10.1056/NEJMoa1506597. View

Heller G, Mo Q . Estimating the concordance probability in a survival analysis with a discrete number of risk groups. Lifetime Data Anal. 2015; 22(2):263-79. PMC: 4886856. DOI: 10.1007/s10985-015-9330-3. View

Harrison L, Guillem J, Paty P, Cohen A . Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg. 1997; 185(1):55-9. DOI: 10.1016/s1072-7515(97)00012-4. View

Fearon E, Huang E . CDX2: Linking Cell and Patient Fates in Colon Cancer. Cell Stem Cell. 2016; 18(2):168-9. PMC: 5497577. DOI: 10.1016/j.stem.2016.01.011. View

Fletcher R . Carcinoembryonic antigen. Ann Intern Med. 1986; 104(1):66-73. DOI: 10.7326/0003-4819-104-1-66. View

Compton C, Fielding L, Burgart L, Conley B, Cooper H, Hamilton S . Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000; 124(7):979-94. DOI: 10.5858/2000-124-0979-PFICC. View

10.

Wanebo H, Rao B, Pinsky C, Hoffman R, Stearns M, Schwartz M . Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med. 1978; 299(9):448-51. DOI: 10.1056/NEJM197808312990904. View

11.

Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C . Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009; 27(19):3109-16. DOI: 10.1200/JCO.2008.20.6771. View

12.

Zhang C, Wang J, Sui B, Zeng Y, Chen J, Dai D . Prognostic and Predictive Model for Stage II Colon Cancer Patients With Nonemergent Surgery: Who Should Receive Adjuvant Chemotherapy?. Medicine (Baltimore). 2016; 95(1):e2190. PMC: 4706247. DOI: 10.1097/MD.0000000000002190. View

13.

Gill S, Loprinzi C, Sargent D, Thome S, Alberts S, Haller D . Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. J Clin Oncol. 2004; 22(10):1797-806. DOI: 10.1200/JCO.2004.09.059. View

14.

Puppa G, Sonzogni A, Colombari R, Pelosi G . TNM staging system of colorectal carcinoma: a critical appraisal of challenging issues. Arch Pathol Lab Med. 2010; 134(6):837-52. DOI: 10.5858/134.6.837. View

15.

Mittendorf E, Vila J, Tucker S, Chavez-MacGregor M, Smith B, Fraser Symmans W . The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment. JAMA Oncol. 2016; 2(7):929-36. PMC: 5757376. DOI: 10.1001/jamaoncol.2015.6478. View

16.

Amri R, Bordeianou L, Sylla P, Berger D . Preoperative carcinoembryonic antigen as an outcome predictor in colon cancer. J Surg Oncol. 2013; 108(1):14-8. DOI: 10.1002/jso.23352. View

17.

Chu D, Erickson C, Russell M, Thompson C, Lang N, Broadwater R . Prognostic significance of carcinoembryonic antigen in colorectal carcinoma. Serum levels before and after resection and before recurrence. Arch Surg. 1991; 126(3):314-6. DOI: 10.1001/archsurg.1991.01410270054010. View

18.

Sobin L . TNM: evolution and relation to other prognostic factors. Semin Surg Oncol. 2003; 21(1):3-7. DOI: 10.1002/ssu.10014. View

19.

Giessen-Jung C, Nagel D, Glas M, Spelsberg F, Lau-Werner U, Modest D . Preoperative serum markers for individual patient prognosis in stage I-III colon cancer. Tumour Biol. 2015; 36(10):7897-906. DOI: 10.1007/s13277-015-3522-z. View

20.

Lucha Jr P, Rosen L, Olenwine J, Reed 3rd J, Riether R, Stasik Jr J . Value of carcinoembryonic antigen monitoring in curative surgery for recurrent colorectal carcinoma. Dis Colon Rectum. 1997; 40(2):145-9. DOI: 10.1007/BF02054978. View